50 related articles for article (PubMed ID: 9728927)
1. Approach to withdrawal from tacrolimus in a fully allogeneic murine skin graft model.
Uchiyama H; Kong Y; Kishihara K; Sugimachi K; Nomoto K
Immunology; 1999 Jun; 97(2):294-300. PubMed ID: 10447745
[TBL] [Abstract][Full Text] [Related]
2. Effect of lethal total body irradiation on bone marrow chimerism, acute graft-versus-host disease, and tumor engraftment in mouse models: impact of different radiation techniques using low- and high-energy X-rays.
To NH; Pilon C; Moatti A; Debesset A; Debbi K; Coraggio G; Ksouri W; Massaria V; Cohen JL; Belkacemi Y; Thiolat A
Strahlenther Onkol; 2023 Dec; 199(12):1242-1254. PubMed ID: 36932237
[TBL] [Abstract][Full Text] [Related]
3. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.
Xu H; Chilton PM; Tanner MK; Huang Y; Schanie CL; Dy-Liacco M; Yan J; Ildstad ST
Blood; 2006 Nov; 108(10):3611-9. PubMed ID: 16888094
[TBL] [Abstract][Full Text] [Related]
4. Loss of early myeloid donor cell engraftment into the central nervous system with nonmyeloablative conditioning.
Nolan EE; Durose W; Taghizadeh LA; King CJ; Gupta AO; Orchard PJ; Lorentson M; Braaten K; Furcich JW; Lund TC
Blood Adv; 2023 Dec; 7(23):7290-7294. PubMed ID: 37871310
[No Abstract] [Full Text] [Related]
5. Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective.
Yolcu ES; Shirwan H; Askenasy N
Stem Cells Transl Med; 2017 Mar; 6(3):700-712. PubMed ID: 28186688
[TBL] [Abstract][Full Text] [Related]
6. Dissociation between peripheral blood chimerism and tolerance to hindlimb composite tissue transplants: preferential localization of chimerism in donor bone.
Rahhal DN; Xu H; Huang WC; Wu S; Wen Y; Huang Y; Ildstad ST
Transplantation; 2009 Sep; 88(6):773-81. PubMed ID: 19920776
[TBL] [Abstract][Full Text] [Related]
7. Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.
Jankowski RA; Ildstad ST
Hum Immunol; 1997 Feb; 52(2):155-61. PubMed ID: 9077564
[TBL] [Abstract][Full Text] [Related]
8. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
9. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment.
Gammie JS; Li S; Colson YL; Demetris AJ; Neipp M; Ildstad ST; Pham SM
Exp Hematol; 1998 Sep; 26(10):927-35. PubMed ID: 9728927
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
[TBL] [Abstract][Full Text] [Related]
11. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.
Foster RD; Pham S; Li S; Aitouche A
Transplantation; 2003 Sep; 76(6):988-94. PubMed ID: 14508367
[TBL] [Abstract][Full Text] [Related]
12. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
Colson YL; Li H; Boggs SS; Patrene KD; Johnson PC; Ildstad ST
J Immunol; 1996 Oct; 157(7):2820-9. PubMed ID: 8816385
[TBL] [Abstract][Full Text] [Related]
13. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
14. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
